Literature DB >> 12457285

Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography.

M Scherr1, K Battmer, M Eder, S Schüle, H Hohenberg, A Ganser, M Grez, U Blömer.   

Abstract

Lentiviral vectors have been shown to stably transduce dividing and non-dividing target cells in vitro and in vivo. However, in vivo gene transfer applications with viral vectors in the central nervous system require highly efficient vector preparations, because only very small volumes can be injected stereotactically without damage to the brain tissue. Since lentiviral vectors are generated in transient co-transfection systems, viral preparations need to be purified and efficiently concentrated before injection into the brain. We describe an alternative procedure to concentrate lentiviral preparations by binding viral particles to an anion exchange column. Viral particles are eluted with sodium chloride, desalted and further concentrated by ultrafiltration. These vector preparations allowed high levels of gene transfer into terminally differentiated neuronal and glial cells and long-term transgene expression without any signs of acute and long-term toxicity or inflammation. The purification of lentiviral vectors from large-scale preparations by anion exchange chromatography allowed us to concentrate the virus to small volumes and to use these preparations to genetically modified target cells in vivo without signs of acute inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457285     DOI: 10.1038/sj.gt.3301848

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

1.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 2.  Lentiviral transgenesis.

Authors:  Alexander Pfeifer
Journal:  Transgenic Res       Date:  2004-12       Impact factor: 2.788

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

4.  Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Separating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in rats.

Authors:  David M Markusic; Dirk R de Waart; Jurgen Seppen
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

6.  Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration.

Authors:  Katrin Zimmermann; Oliver Scheibe; Andreas Kocourek; Jutta Muelich; Elke Jurkiewicz; Alexander Pfeifer
Journal:  BMC Biotechnol       Date:  2011-05-20       Impact factor: 2.563

7.  Lentiviral gene transfer into the dorsal root ganglion of adult rats.

Authors:  Hongwei Yu; Greg Fischer; Guangfu Jia; Jakob Reiser; Frank Park; Quinn H Hogan
Journal:  Mol Pain       Date:  2011-08-23       Impact factor: 3.395

8.  A Molecular Toolbox for Rapid Generation of Viral Vectors to Up- or Down-Regulate Neuronal Gene Expression in vivo.

Authors:  Melanie D White; Ruth V J Milne; Matthew F Nolan
Journal:  Front Mol Neurosci       Date:  2011-07-04       Impact factor: 5.639

9.  Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography.

Authors:  Robert H Kutner; Sharon Puthli; Michael P Marino; Jakob Reiser
Journal:  BMC Biotechnol       Date:  2009-02-16       Impact factor: 2.563

Review 10.  Production of lentiviral vectors.

Authors:  Otto-Wilhelm Merten; Matthias Hebben; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-13       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.